D. Whitcomb

发表

Randomized phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non–small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2016 .

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2017, British Journal of Cancer.

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

G. Giaccone, G. Oxnard, A. Krivoshik, 2016 .

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.

G. Giaccone, G. Oxnard, A. Krivoshik, 2015 .